Compare VRTX & PDD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VRTX | PDD |
|---|---|---|
| Founded | 1989 | 2015 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | EDP Services | Business Services |
| Sector | Technology | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 123.4B | 118.4B |
| IPO Year | 2006 | 2018 |
| Metric | VRTX | PDD |
|---|---|---|
| Price | $556.43 | $82.25 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 29 | 9 |
| Target Price | ★ $539.69 | $139.22 |
| AVG Volume (30 Days) | 1.1M | ★ 6.1M |
| Earning Date | 05-04-2026 | 05-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 836.54 | N/A |
| EPS | ★ 8.33 | N/A |
| Revenue | ★ $2,488,652,000.00 | N/A |
| Revenue This Year | $10.79 | $15.35 |
| Revenue Next Year | $10.47 | $12.63 |
| P/E Ratio | $66.87 | ★ $10.63 |
| Revenue Growth | ★ 46.20 | N/A |
| 52 Week Low | $374.17 | $71.94 |
| 52 Week High | $558.36 | $139.41 |
| Indicator | VRTX | PDD |
|---|---|---|
| Relative Strength Index (RSI) | 65.84 | 38.20 |
| Support Level | $425.34 | $71.94 |
| Resistance Level | $555.69 | $107.53 |
| Average True Range (ATR) | 11.76 | 2.23 |
| MACD | 0.10 | -0.78 |
| Stochastic Oscillator | 90.80 | 10.72 |
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
PDD Holdings operates commerce businesses globally. Its main operations are Pinduoduo, a social commerce platform in China, and Temu, a global e-commerce marketplace. PDD also has a community group purchase business in China. PDD has built a network of sourcing, logistics, and fulfillment capabilities that support its underlying businesses. PDD has also started its first-party brand business for global markets.